Annual report 2017

• The potential was demonstrated of CBCT radiomics to be used as prognostic imaging biomarker Work package 7 Dose-escalation by boosting radiation within primary tumour based on a pre-treatment FDG- PET-scan in NSCLC: randomised phase II trial: • patient accrual ended in October 2017 with 107 randomised and 150 registered patients • completion of analysis of data will end in 2018

Work package 8 Phase III head and neck clinical trial: a randomised study with cisplatin or cetuximab and standard or adaptive high dose radiotherapy for advanced head and neck cancer: • patient accrual started and has reached 181 and will end in 2019

For more information, visit: www.cancerartforce.eu

71

SCIENCE DISSEMINATION